BTIG Remains a Hold on Edwards Lifesciences (EW)

BTIG analyst Marie Thibault maintained a Hold rating on Edwards Lifesciences (EWResearch Report) today. The company’s shares closed last Friday at $110.66, close to its 52-week high of $111.96.

According to, Thibault is a 5-star analyst with an average return of 60.2% and a 63.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Boston Scientific.

Currently, the analyst consensus on Edwards Lifesciences is a Strong Buy with an average price target of $121.00, a 6.7% upside from current levels. In a report released today, Deutsche Bank also maintained a Hold rating on the stock with a $113.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $111.96 and a one-year low of $70.92. Currently, Edwards Lifesciences has an average volume of 2.36M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.